Low-Grade Serous Carcinoma of the Ovary: A Distinct Disease, Not a Mild One

What it is, and where it sits in the classification

Low-grade serous carcinoma (LGSC) is a recognized subtype of ovarian serous carcinoma in the WHO Classification of Tumours, 5th edition [1]. The word "low-grade" invites a misunderstanding that's worth correcting at the outset: LGSC is not a well-behaved version of high-grade serous carcinoma (HGSC). It is a biologically separate entity with its own precursor, its own driver mutations, and its own clinical tempo. The two diseases sit at opposite poles of what pathologists call the dualistic model of ovarian serous carcinogenesis — HGSC arising through catastrophic TP53 dysfunction, LGSC arising along a slower, stepwise route from a serous borderline tumor [1].

That developmental origin matters. LGSC frequently arises from, or coexists with, a serous borderline tumor, and this association is one of its two defining features [1]. Trainees frequently underestimate how much diagnostic weight the borderline-tumor background carries. When you find low-grade serous glands sitting alongside recognizable borderline architecture, the differential narrows fast.

How a pathologist recognizes it: morphology first

Diagnosis begins down the microscope, and LGSC has a characteristic look. The architecture is papillary and micropapillary, often with hierarchical branching that echoes its borderline ancestry [1]. The single most useful clue, though, is nuclear: the cells are uniform, with low-grade nuclei that show minimal pleomorphism and only modest variation in size and shape. The mitotic rate is low [1]. If you're seeing brisk mitoses, bizarre nuclei, or the kind of nuclear anarchy that makes you reach for a gown, you're almost certainly not looking at LGSC — that's the visual signature of high-grade disease.

This uniformity is the crux. The distinction between LGSC and HGSC rests heavily on nuclear grade, and when the grade is genuinely ambiguous, morphology alone won't settle the argument. That's when the workup moves to immunohistochemistry.

Then IHC, in that order

The immunoprofile of LGSC confirms serous lineage and, critically, separates it from its high-grade counterpart. LGSC is positive for WT1 and PAX8, consistent with a Müllerian serous phenotype [1].

The decisive stain is p53. LGSC shows a wild-type p53 pattern — scattered, heterogeneous nuclear staining of variable intensity, reflecting an intact TP53 gene [1]. HGSC, by contrast, shows an aberrant pattern: either strong and diffuse block-positive staining or, in the null variant, complete absence of expression. The p53 stain is the one I return to most often when the nuclear grade sits on the fence. It's worth stressing the failure mode here, because it trips people up: a diffuse strong stain is abnormal, and a completely negative stain is also abnormal. Wild-type is the messy, patchy, in-between look — and that messiness is exactly what you want to see in LGSC. Reading "negative" as "normal" is a classic beginner's error that flips the diagnosis in precisely the wrong direction.

Molecular confirmation

Molecular findings reinforce what morphology and IHC have already suggested. LGSC is driven by mutations in the MAPK signaling pathway — most commonly KRAS, BRAF, or NRAS [1]. In practical terms, "MAPK-pathway driven" means the tumor's growth is powered by a constitutively activated intracellular signaling cascade that normally relays proliferation cues from the cell surface to the nucleus; a single activating mutation jams that switch in the "on" position. Consistent with the wild-type p53 immunostain, TP53 is not mutated in LGSC [1]. This molecular signature is the mirror image of HGSC, where TP53 mutation is essentially universal and MAPK driver mutations are not the defining event.

A word on the differential: endometrioid carcinoma

The trap that catches trainees most often isn't HGSC — it's low-grade endometrioid carcinoma. Both are low-grade Müllerian tumors, both can form small papillary or glandular structures, and both can look deceptively bland on H&E. Morphology alone can genuinely mislead you here, and that's where a focused immunopanel earns its keep. WT1 positivity supports serous lineage and argues against endometrioid carcinoma, which is typically WT1-negative [1]. PAX8 doesn't help discriminate, since both are positive [1]. When the architecture is equivocal, don't try to force the call on H&E — let the panel arbitrate.

Grading and classification

LGSC is a distinct diagnostic entity rather than a grade assigned within the serous carcinoma family [1]. This is a subtle but important point of taxonomy: calling a tumor "low-grade serous carcinoma" is not the same as saying "serous carcinoma, low grade." It commits you to a specific disease with a specific biology. The two-tier framework — low-grade versus high-grade serous carcinoma — reflects two distinct pathways, not a continuous spectrum of aggressiveness [1].

Why the distinction matters clinically

Here's where the biology stops being academic. LGSC is more indolent than HGSC, following a slower clinical course — yet it is comparatively chemo-resistant [1]. That combination surprises clinicians meeting the disease for the first time: instinct says a slow-growing, low-grade tumor should be the easy one to treat, and it often isn't. The very features that make LGSC less aggressive — low proliferation, genomic stability, intact p53 — also make it less vulnerable to cytotoxic agents that preferentially kill rapidly dividing cells.

The MAPK-pathway dependence points toward a mechanistically rational therapeutic class: MEK inhibitors, which target that signaling axis [1]. This is a matter of drug-class eligibility informed by tumor biology, not treatment advice for any individual, and the field continues to evolve.

If there's a single practical lesson to carry away from an ambiguous serous case, it's this: the p53 stain resolves more diagnostic standoffs than the nuclei do, and reading its wild-type pattern correctly — patchy, not blank — is what keeps a genuine LGSC from being misfiled as high-grade. Getting that call right reroutes the entire understanding of the disease in front of you, from expected behavior to the biology that will drive it.

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. Lyon: IARC; 2020. ISBN 978-92-832-4504-9.